Use

Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
Tuesday, March 5, 2024
Health Technology, Diabetes, Manufacturing, Technology, Pharmaceutical, Other Consumer, General Health, Medical Devices, Clinical Trials, Wearables, Mobile Technology, Other Manufacturing, Science, Consumer, Health, Research, Real-World Evidence, Cloud, OBE, Adolescence, Doctor of Philosophy, Treatment, Medical director, Database, University, Hypoglycemia, Associate, AID, University of Liverpool, Standard of care, Data, Therapy, Insulin, Convention, Randomized controlled trial, CGM, Pathway, Use, Conference, MDI, Automation, Endocrinology, MD, DASH, ATTD, Medicare, University of Edinburgh, Edge Hill University, Corporation, Chairperson, Medical device

“We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.

Key Points: 
  • “We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.
  • It is the first Omnipod 5 randomized controlled trial to date, and the first time the system has been evaluated in participants living outside of the United States.
  • This presentation will take place on Thursday, March 7 at 12:00 p.m. CET and Friday, March 8 at 10:30 a.m. CET.
  • Insulet representatives will be available to provide Omnipod product demonstrations to conference attendees, offering healthcare professionals the chance to experience Omnipod DASH and Omnipod 5 first-hand.

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Retrieved on: 
Wednesday, February 28, 2024
Oncology, Professional Services, Health, Finance, General Health, Pharmaceutical, Biotechnology, CANF, Non-alcoholic fatty liver disease, Psoriasis, CMS, Liver disease, ALT, Fatty liver disease, Patent, Use, Inflammation, CKD, Human, Partner, Patient, IP, NASH, Phase, American Liver Foundation, Pharmaceutical industry

(NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application titled “An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation”.

Key Points: 
  • (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application titled “An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation”.
  • This invention addresses the use of Namodenoson for the reduction of liver fat in patients with NASH a clinical indication that is being developed by Can-Fite.
  • The Company also has a distribution agreement in Canada for its anti-inflammatory drug, Piclidenoson, for the treatment of psoriasis.
  • “This additional patent in Canada for fatty liver disease adds to our growing IP estate for this high-value indication of the Namodenoson drug candidate.

Elastic Reports Third Quarter Fiscal 2024 Financial Results

Retrieved on: 
Thursday, February 29, 2024
Apps, Applications, Technology, Mobile, Wireless, Security, Software, Networks, Internet, Data Management, Artificial Intelligence, Cloud, Total, Service level, United States dollar, Hugging Face, Azure, Elasticsearch, Generative, Growth, Use, Microsoft Azure, Synthetic media, ACV, GAAP, Webcast, Service-level objective, SLO, ESTC, Microsoft, GAI, Environment, Cryptocurrency

Elastic (NYSE: ESTC) (“Elastic”), the company behind Elasticsearch®, announced financial results for its third quarter of fiscal 2024 ended January 31, 2024.

Key Points: 
  • Elastic (NYSE: ESTC) (“Elastic”), the company behind Elasticsearch®, announced financial results for its third quarter of fiscal 2024 ended January 31, 2024.
  • We present historical and forward-looking non-GAAP financial measures in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.
  • See the section entitled “Statement Regarding Use of Non-GAAP Financial Measures” for an explanation of these non-GAAP measures.
  • There was no impact to operating results, non-GAAP diluted earnings per share, adjusted free cash flow or cash and cash equivalents.

KBRA Assigns AA- Rating to Clark County, NV's Airport System Subordinate Lien Refunding Revenue Bonds Series 2024A (Non-AMT), and A+ Rating to Airport System Junior Subordinate Lien Revenue Notes Series 2024B (Non-AMT)

Retrieved on: 
Wednesday, February 28, 2024
Professional Services, Air, Transport, Finance, Use, CIP, KBRA, Note, Risk, Casino

Strong liquidity and satisfactory debt service coverage margins, given the residual Use and Lease Agreement.

Key Points: 
  • Strong liquidity and satisfactory debt service coverage margins, given the residual Use and Lease Agreement.
  • Declining annual debt service requirements and an absence of expected borrowing in CIP.
  • Leisure and hospitality base could be vulnerable in a severe economic downturn and competitive pressures.
  • Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at www.kbra.com .

Snowflake Reports Financial Results for the Fourth Quarter and Full-Year of Fiscal 2024

Retrieved on: 
Wednesday, February 28, 2024
Data Management, Security, Technology, Software, Networks, Artificial Intelligence, Internet, Cloud, Employee stock purchase plan, Intelligence, Net, Tag cloud, Marketing, Snowflake Inc., Table, Use, Growth, Access, Holiday, RPO, GAAP, Webcast, Uncertainty, Security (finance), Snowflake, Bank statement, Environment

See the section titled “Statement Regarding Use of Non-GAAP Financial Measures” for an explanation of non-GAAP financial measures.

Key Points: 
  • See the section titled “Statement Regarding Use of Non-GAAP Financial Measures” for an explanation of non-GAAP financial measures.
  • We have provided a reconciliation of GAAP to non-GAAP financial measures in the financial statement tables for our historical non-GAAP financial results included in this release.
  • Non-GAAP Product gross profit, Operating income, Net income, Net income attributable to Snowflake Inc., and Net income per share attributable to Snowflake Inc. common stockholders - basic and diluted.
  • We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons.

indie Semiconductor Achieves Record Fourth Quarter and 2023 Results

Retrieved on: 
Thursday, February 22, 2024
Software, Technology, Semiconductor, Toyota, General Motors, Telephone, Original equipment manufacturer, Use, Conference, Vision, BMW, GAAP, Morgan Stanley, Ford, Finance, Radar, Artificial intelligence, Internet, Video game

indie Semiconductor, Inc. (Nasdaq: INDI), an Autotech solutions innovator, today announced fourth quarter and year end results for the period ended December 31, 2023.

Key Points: 
  • indie Semiconductor, Inc. (Nasdaq: INDI), an Autotech solutions innovator, today announced fourth quarter and year end results for the period ended December 31, 2023.
  • Fourth quarter revenue was up 112 percent from the same period a year ago and 16 percent sequentially to a record $70.1 million, within the Company’s prior guidance range.
  • On a GAAP basis, fourth quarter 2023 operating loss was $20.6 million compared to $29.0 million a year ago.
  • Non-GAAP operating loss for the fourth quarter of 2023 was $2.4 million, versus $15.1 million during the same period last year, reflecting higher revenue, improving gross margin and operating expense leverage.

The BioCollective® Awarded Groundbreaking Probiotic Patent

Retrieved on: 
Thursday, March 7, 2024
Ecology, The, Diabetes, Parkinson's disease, Probiotic, Human microbiome, Carbohydrate metabolism, Pediococcus acidilactici, Blood, Patent, Use, Disease, Health, Type 2 diabetes, Triglyceride, Leuconostoc mesenteroides, DSM-IV codes, Patient, Insulin, United States patent law, Clinical trial, Research, Dietary supplement

DENVER, March 7, 2024 /PRNewswire-PRWeb/ -- The BioCollective, a pioneer in microbiome research and consumer probiotics, today announced it has been granted a patent for a system of probiotics to manage and potentially treat a range of significant health issues.

Key Points: 
  • The issued composition-of-matter patent covers probiotic formulations to prevent or limit disease conditions, restore lost physiological function, and reduce gastrointestinal infection by modulating gastrointestinal mannitol.
  • The patent covers a range of clinical conditions, including diabetes, metabolic diseases, gastrointestinal infections, and neurological diseases.
  • The US Patent and Trademark Office issued US Patent No.
  • The company's BiotiQuest® Sugar Shift® probiotic and additional products in its development pipeline are covered under the patent.

Digital Surgery Technologies Market Report 2024 - Improved Precision and Promising Post-Operative Rehabilitation through Pre-Surgical Planning

Retrieved on: 
Wednesday, March 6, 2024
Real-World Evidence, Investment, Name, Virtual reality, Hospital, University of Miyazaki, Algorithm, Privacy, AI, Education, Traction, Research, ROI, Digital, Pain, 3D, Growth, Johnson & Johnson, Use, Surgeon, Government, RWE, Country, Immersion, Health care, Interest, Patient, Region, Acceleration, Medicine, Patient safety, VR, Trust, Augmented reality, Microsoft, Software, Dentistry

The key factors driving the growth of the global digital surgery technologies market include the increasing interest of technologists and start-ups in surgery-related innovation, improved precision offered by digital surgery techniques, and promising post-operative rehabilitation through pre-surgical planning.

Key Points: 
  • The key factors driving the growth of the global digital surgery technologies market include the increasing interest of technologists and start-ups in surgery-related innovation, improved precision offered by digital surgery techniques, and promising post-operative rehabilitation through pre-surgical planning.
  • Increasing Investment and Funding for Digital Surgery Technologies: Digital surgery technologies, owing to their transformative potential to enhance precision, optimize workflows, and improve patient outcomes, are rapidly changing the landscape of healthcare.
  • Investing in digital surgery technologies is not just about financial gains; it's an investment in the future of healthcare.
  • Based on application, the digital surgery technologies market has been led by augmented reality and virtual reality, which held a 48.40% share in 2022.

Birdeye Launches AI-powered Social Platform for Multi-Location Brands

Retrieved on: 
Wednesday, March 6, 2024
PALO, Social media, Marketing, Calendar, AI, Use, Publishing, Feedback, Create, Generate, Head, Heart

PALO ALTO, Calif., March 6, 2024 /PRNewswire/ -- Birdeye, the leading reputation and customer experience platform for local businesses is proud to announce the launch of Birdeye Social. This cutting-edge platform harnesses the power of AI to revolutionize social media management from content generation to monitoring and reporting for multi-location enterprises.

Key Points: 
  • Birdeye Social powers social media management, content generation, monitoring, and reporting
    PALO ALTO, Calif., March 6, 2024 /PRNewswire/ -- Birdeye, the leading reputation and customer experience platform for local businesses is proud to announce the launch of Birdeye Social.
  • "Birdeye Social sets a new standard for local social media management," said Dave Lehman, President at Birdeye.
  • "Unlike existing solutions, which often overlook the complex needs of multi-location brands, our platform is purpose-built to address the challenges of scaling social media management across hundreds of locations."
  • At the heart of Birdeye Social is BirdAI, a cutting-edge generative AI engine that simplifies the process of creating engaging social media content.

Global Embedded Finance Ecosystem Report 2024: Mapping the Path to Services Industries' Transformation - Focus on Mobility, Travel, Foodservice, and Healthcare

Retrieved on: 
Tuesday, March 5, 2024
Path, Health, Growth, Use, Credit, Payment, Environment

DUBLIN, March 5, 2024 /PRNewswire/ -- The "Embedded Finance Ecosystem: Mapping the Path to Services Industries' Transformation" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 5, 2024 /PRNewswire/ -- The "Embedded Finance Ecosystem: Mapping the Path to Services Industries' Transformation" report has been added to ResearchAndMarkets.com's offering.
  • The Embedded Finance Ecosystem: Mapping the Path to Services Industries' Transformation global briefing offers insight into the size and shape of the Consumer Finance market, highlights buzz topics, emerging geographies, categories and trends as well as pressing industry issues and white spaces.
  • Embedded finance is the critical factor to improve customer journey and drive transformation for services industries.. With travel recovery and sluggish volume sales of automotives, embedded finance is considered to have the most potential to build and enhance partnerships to support their market value sales growth.
  • The briefing leverages the publisher's 360-degree coverage of the global payments' landscape including insight on consumer debt.